Search, analyze, export, and monitor psilocybin and psilocin literature across peer-reviewed papers, preprints, reviews, protocols, and clinical trials.
| Source | Count | Share | Status |
|---|---|---|---|
| Europe PMC | 2,560 | 64.5% | Active |
| PubMed | 302 | 7.6% | Active |
| ClinicalTrials.gov | 287 | 7.2% | Active |
| OpenAlex | 264 | 6.7% | Active |
| PsyArXiv | 216 | 5.4% | Active |
| Crossref | 161 | 4.1% | Active |
| bioRxiv | 142 | 3.6% | Active |
Most recently published records currently stored in SQLite.
Neuropsychopharmacology Reports · 2026-08-31
The Brown University Psychopharmacology Update · 2026-07-31
ClinicalTrials.gov · 2026-07-01
Journal of Drug Issues · 2026-06-30
ClinicalTrials.gov · 2026-06-30
The Brown University Psychopharmacology Update · 2026-06-30
The Brown University Psychopharmacology Update · 2026-06-30
Journal of Affective Disorders Reports · 2026-06-30
Palliative medicine · 2026-06-30
British journal of pharmacology · 2026-06-30
British journal of pharmacology · 2026-06-30
British journal of pharmacology · 2026-06-30
British journal of pharmacology · 2026-06-30
The fungivore-deterrence hypothesis, that psilocybin evolved as a chemical defence against arthropod fungivores via 5-HT receptor agonism, has become the working consensus in fungal chemical ecology, despite resting on a phylogenomic pattern of horizontal gene transfer among saprotrophs and remarkably little direct experimental evidence. Recent biochemistry ...
RationaleInterest in psychedelic drugs has increased rapidly because of their potential therapeutic role in psychiatric disorders. Impairments in the sociocognitive skills needed to build and maintain social relationships are prominent features of many psychiatric and neurodevelopmental disorders. Emerging evidence suggests that compounds such as 3,4-methyle...
Psilocybin has been shown to induce fast and sustained symptoms improvements across various psychiatric conditions, yet its long-term mechanisms of action are not fully understood. Initial evidence suggests that longitudinal functional and structural brain changes implicate fronto-striatal-thalamic (FST) circuitry, a broad system involved in goal-directed be...
ImportancePsychedelic drugs possess acute psychoactive effects that can compromise blinding integrity in randomized clinical trials (RCTs). Functional unblinding, when participants or raters correctly identify treatment allocation based on subjective effects, may bias outcomes through expectancy effects, challenging the validity of efficacy estimates and reg...
Mental disorders represent a major global health problem, with depression being one of the most prevalent and disabling conditions worldwide. Growing evidence suggests that the serotonergic system, particularly the 5-HT2A receptor, plays an important role in modulating mood and cognitive processes, constituting a key pharmacological target for several psycho...
BackgroundAnorexia nervosa (AN) is a severe psychiatric disorder with high morbidity, mortality, and relapse rates, most commonly emerging during adolescence. Despite specialized psychological and nutritional treatments, outcomes remain suboptimal, with high rates of relapse and chronicity. Psilocybin has been investigated with preliminary efficacy in other ...
Psilocin (4-hydroxy-N, N-dimethyltryptamine) is a substituted tryptamine alkaloid and a nonselective serotonergic agonist acting predominantly at 5-HT2A/C receptors, with substantial binding to 5-HT1A and 5-HT2B receptors. Microdosing is the practice of taking a very small, sub-perceptual dose, typically 5% to 10% of a full recreational dose, to improve mood...
PurposeMajor depressive disorder (MDD) is a heterogeneous, debilitating disorder. A distinct subgroup within the MDD spectrum is identified to have treatment-resistant depression (TRD). There is an impetus to find alternative treatments for TRD to reduce disease burden and improve quality of life. Psychedelics have been used in the treatment of various psych...
BackgroundPsychedelic microdosing-repeated sub-perceptual doses of lysergic acid diethylamide (LSD) or psilocybin-has attracted scientific interest as a potential mood and cognitive intervention. The evidence base remains methodologically heterogeneous and vulnerable to expectancy bias.MethodsWe conducted an umbrella review with narrative synthesis following...
BackgroundPosttraumatic stress disorder (PTSD) and major depressive disorder are often comorbid in humans. Psilocybin reportedly has beneficial therapeutic effects on depression, possibly by promoting neuroplasticity. PTSD is associated with the dysregulation of neuroplasticity in the hippocampus and medial prefrontal cortex (mPFC). We hypothesized that psil...
With growing research on the use of psychedelics to treat mental health conditions, greater attention to the psychosocial procedures accompanying substance administration is warranted. This scoping review aims to categorize psychosocial protocols used in research involving psychedelics as psychiatric treatment according to their purpose, denomination, format...
An increasing number of U.S. states are implementing or considering alternative policies to the prohibition of some psychedelic substances for nonclinical purposes. The authors present new data and analysis to inform these discussions with survey results on the use of 11 psychedelic substances and detailed information about the prevalence of microdosing (i.e...
Major depressive disorder (MDD) and treatment-resistant depression (TRD) are prevalent and debilitating conditions. Over 50% of patients have inadequate response to first-line serotonergic antidepressants and are left with suboptimal treatment options. Rapid-acting and individually tailored treatments for MDD remain major unmet needs. This review discusses p...
A prominent theory of psychedelics is that they increase brain entropy. Thirteen studies have evaluated psychedelic effects on fMRI brain entropy, each applying a distinct measure. Here we evaluated these metrics in an independent 28-participant healthy cohort with 121 pre- and post-psilocybin fMRI scans. We assessed relations between brain entropy and objec...
BackgroundMajor depressive disorder is one of the most debilitating psychiatric disorders worldwide. First-line treatments such as selective serotonin reuptake inhibitors have significant limitations, including delayed onset of therapeutic effects and treatment resistance in about 30% of patients. Increasing evidence suggests that acute administration of ser...
Abstract Rationale: Major depressive disorder (MDD) shows marked sex differences in prevalence, symptomatology, and treatment response. However, women remain underrepresented in many clinical trials, and sex-specific treatment outcomes are rarely examined. Objectives This study reanalyzed data from a randomized controlled trial comparing psilocybin and escit...
Given the increases in psychedelic use, we examined correlates of psychedelic use and use motives among US young adults. In 2025, adults ages 18-34 (n = 3,227; Mage = 26.38, ~50% past-month cannabis use by design) completed an online survey. Multivariable regression assessed sociodemographics, mental health, and adverse childhood events (ACEs) in relation to...
IntroductionUnderstanding retailer advertising has been identified as critical for developing effective policies to reduce tobacco product use, as these forms of advertising are among the tobacco industry's largest expenditures. Online retailer marketing has grown rapidly, and in this study, we sought to describe the marketing practices of these retailers.Me...
Fibromyalgia (FM) is a chronic nociplastic pain syndrome characterised by widespread pain, fatigue, sleep disturbances and cognitive impairment, with a significant impact on health-related quality of life (HRQoL). Despite the availability of several therapeutic options, management remains challenging and often requires a personalised and multidimensional app...
